Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,261 across all filing types
Latest filing 2023-11-09 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
At the Board Meeting of the Company held on Thursday, November 9, 2023, the Board of Directors considered and approved the Unaudited Financial Results for the quarter ended September 30, 2023.
Regulatory Filings
2023-11-09 English
Board Meeting — ASTRAZENECA PHARMA INDIA LIMITED has informed the Exchange about Board Meeting to be held on 09-Nov-2023 to inter-alia consider and approve the Unaudited Financial results of the Comp…
Regulatory Filings
2023-10-31 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about an upcoming Board of Directors meeting scheduled for November 9, 2023. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2023. The document also mentions the closure of the trading window for insiders. The document is short (1514 characters) and serves as a notification of a future event rather than containing any financial data or results itself. It does not contain actual financial statements or detailed analysis, nor is it a transcript, audit report, or any other detailed report. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for such announcements and notifications to exchanges.
2023-10-30 English
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 ,inter alia, to consider and approve The Unaudited Financial ....
Board/Management Information Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about an upcoming Board of Directors meeting scheduled for November 9, 2023. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2023. The document also mentions the closure of the trading window for insiders. The document is short (1514 characters) and serves as a notification of a future event rather than containing actual financial results or detailed reports. It does not contain financial statements or substantive financial data itself, so it is not an Interim/Quarterly Report (IR). Instead, it is an announcement related to corporate governance and board activities. Therefore, the most appropriate classification is Board/Management Information (MANG).
2023-10-30 English
Updates
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about a regulatory order received from the Transfer Pricing Officer related to an assessment year 2021-22. It includes details of the dispute, financial implications, and the company's intention to challenge the order. The document is addressed to stock exchanges and is a regulatory announcement rather than a financial report or detailed audit. It does not contain financial statements or detailed financial analysis but is a compliance disclosure about a legal/regulatory matter. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document.
2023-10-29 English
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform that the Company has received an order from the Transfer Pricing Officer being issued under Section 92CA(3) ....
Legal Proceedings Report Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about a tax assessment order received from the Transfer Pricing Officer for the assessment year 2021-22. It includes details of the dispute, the opposing party, and the expected financial implications. The document is addressed to stock exchanges and is a regulatory disclosure about a legal/tax matter. It does not contain financial statements or detailed financial analysis, nor is it a full audit or annual report. It is an update on a legal proceeding related to tax assessment. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is 2661 characters, which is short and focused on a legal/regulatory update rather than a full report or announcement of a report publication. Hence, the classification is LTR with high confidence.
2023-10-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.